<pre id="9ffdh"></pre>
    <p id="9ffdh"></p>
    <pre id="9ffdh"></pre>
    <p id="9ffdh"></p>
          <ruby id="9ffdh"><b id="9ffdh"><thead id="9ffdh"></thead></b></ruby>

          <pre id="9ffdh"></pre>



          Name:Lauromacrogol Injection

          【Content】This product mainly content is Lauromacrogol。

          Chemical Name: Empilan KB

          Chemical structural formula:

          Molecular formula:C12H25(OCH2CH2)nOH( = 9)

          Molecular weight:582.8

          Accessories: ethanol, water for injection


          The product is colorless transparent liquid, shake a few bubbles.


          For emergency endoscopic variceal bleeding and varicose sclerotherapy veins.


          【Usage and dosage】

          Esophageal varices bleeding with activity, surround the bleeding point + direct injection technology to stop bleeding, a bleeding point for local use about 10ml, the maximum does not exceed 15ml. Variceal sclerotherapy, by simple intravenous injection technique, each injection of 2-4 points, each point injection dose of 3-15ml; used by vein - intravenous combined injection technique, in order to by vein injection, began to retrograde sclerotherapy of esophageal 1-2cm away from the dentate line, vein adjacent mucosa under multi-point injection, the injection quantity each point to local injection appears gray white uplift as a standard, usually use no more than 1ml, intravenous injection every bit of 1-2ml, less than 35ml total dose a hardening treatment. Variceal bleeding after the activity, by vein - vein injection sclerotherapy combined technology in other visible with a total dose of varicose veins, hemostasis and hardening treatment does not exceed 35ml. Variceal sclerotherapy 4-6 weeks to complete; for the first time after treatment with second treatment interval not more than a week, then once a week until the visible varicose vein disappeared completely.

          【Adverse reaction】

          There may be a temporary chest pain, heart function and reduce, dysphagia, heartburn, acid reflux, constipation; also can appear local tissue necrosis and ulcer of esophagus (sometimes with hemorrhage, there are individual perforation), esophageal stricture, pleural effusion; occasionally temporary collapse, dizziness, difficulty breathing, chest tightness, nausea, blurred vision and local sensory impairment and metallic taste.


          People who are in a state of shock or allergenic to our product should be prohibited to use.

          The following circumstances according to the illness:

          1. Acute severe heart disease, such as endocarditis, myocarditis, heart failure and hypertension. Within stable condition after the treatment, can perform sclerotherapy.

          2. Pyrexia

          3. Acute lung diseases, including breathing difficulties (e.g., bronchial asthma)


          1. Remember not to inject the arteries.

          2. Should be in strict accordance with the rules of operation for the preoperative preparation and postoperative care.

          【Pregnant and lactating women】

          Foreign reports, in the first 3 months of pregnancy is disabled and after 36 weeks of pregnancy.



          【Drug interactions】

          As a result of lauromacrogol is a local anesthetic agent, has local analgesic effect, when combined with anesthetics when increase the risk of cardiac anesthesia (anti arrhythmia effect).


          【Pharmacology and Toxicology】

          Lauromacrogol injection is a hardening agent. Lauromacrogol injection in varicose vein side can make varicose vein varicose veins surrounding fibrosis, oppression, and reach the purpose of hemostasis; intravenous injection of lauromacrogol, can damage the vascular endothelial cells, promote thrombosis, vascular obstruction, thus to achieve hemostasis.


          【Storage】Sealed, cool and dark place (to avoid light is not more than 20℃) save.



          【Execute standard】The National Food and Drug Administration Standard YBH02612005

          【Approval No.】Guoyao Zhunzi H20080445

          堅持善于求變,與時俱進 TIANYU CHANG’AN GROUP
          寧為蒼狼嘯西風 TIANYU CHANG’AN GROUP
          “頭狼”的力量 TIANYU CHANG’AN GROUP
          藥品生產質量管理規范 TIANYU CHANG’AN GROUP
          而今邁步從頭越 TIANYU CHANG’AN GROUP
          TIANYU CHANG’AN GROUP 2010 (C) all rights reservedOA login Enterprise mailbox login
          Headquarter Add: 3F, No.A Qin Fenge Building, Xi’an Software Park, Keji 2 Road, Hi-tech Zone Xi’an city, China. Tel: 0086-29-88323296 Fax: 0086-29-87607179
          Factory Add: Changqing Road 108, Xi'an Economic and Technological Development Zone, Jinghe River Industrial Park, Xi’an City. Tel:0086-29-86033301
          Code: 710075 Email: CMB@tytiu.com
          Shaanxi ICP No. 08100338
            <pre id="9ffdh"></pre>
            <p id="9ffdh"></p>
            <pre id="9ffdh"></pre>
            <p id="9ffdh"></p>
                  <ruby id="9ffdh"><b id="9ffdh"><thead id="9ffdh"></thead></b></ruby>

                  <pre id="9ffdh"></pre>